HURA

Tuhura Biosciences, Inc. (HURA) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Tuhura Biosciences, Inc. is a clinical-stage immuno-oncology company focused on overcoming resistance to cancer immunotherapies. The company operates in a single segment and has no product revenue. Key product candidates include IFx-2.0 (Phase 3 trial initiated in June 2025 for Merkel cell carcinoma) and TBS-2025 (acquired via the Kineta merger in June 2025, a VISTA-inhibiting antibody for AML).

Key Financial Metrics

Debt and Liquidity: As of March 31, 2026, the company had no long-term debt on the balance sheet, though it had current lease liabilities of $0.21 million. The company holds $6.3 million in cash. In April 2026 (subsequent to the period), the company secured a $50 million revolving credit facility with Parkview Holdings One LLC.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $0.87 million compared to Q1 2025, driven primarily by higher operating expenses.
• Operating Expenses: Total operating expenses rose to $7.53 million from $7.02 million.
  • R&D Expenses: Increased by $0.65 million to $5.23 million. This reflects a $0.52 million increase for the new TBS-2025 program, offset by a $0.75 million decrease in IFx-2.0 costs. Personnel and facility costs increased by $1.03 million due to headcount growth and stock-based compensation.
  • G&A Expenses: Increased by $0.28 million to $2.30 million, largely due to higher stock-based compensation and public company costs.
  • Acquisition Costs: Acquisition-related costs were $0 in Q1 2026 compared to $0.42 million in Q1 2025 (related to the Kineta merger).
• Other Income/Expense: Total other income turned negative at $(0.01) million compared to $0.35 million in the prior year. This was due to the absence of $0.25 million in grant income recorded in Q1 2025 and the incurrence of $0.03 million in interest expense.
• Financing Activity: The company raised approximately $7.5 million in gross proceeds from the issuance of common stock (Registered Direct Offering) in Q1 2026, compared to $0.5 million from warrant exercises in Q1 2025.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing cash resources, combined with the new $50 million Parkview credit facility and the At-The-Market (ATM) offering program, to fund operations into the end of 2028.
• Subsequent Financing: On April 21, 2026, the company entered a $50 million revolving credit facility with Parkview Holdings One LLC. Terms include 12% interest, a $5 million commitment fee (paid via stock issuance), and a royalty agreement on IFx-2.0 net sales. No funds had been drawn as of the filing date.
• ATM Program: Sales under the $50 million ATM program began in April 2026, generating approximately $0.32 million in gross proceeds from 104,000 shares.
• Risks:
  • Capital Needs: The company is not profitable and expects to incur significant losses as it advances clinical trials. Failure to raise additional capital could force delays or termination of programs.
  • Regulatory Uncertainty: Success depends on obtaining regulatory approvals for IFx-2.0 and TBS-2025, which are lengthy and unpredictable.
  • Debt Covenants: The new Parkview facility is secured by substantially all assets and includes covenants that restrict additional debt, asset dispositions, and require prepayments from net profits if achieved.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $6.3 million cash balance against the burn rate of ~$4.4 million per quarter, noting the reliance on the undrawn $50 million credit facility.
• Debt Terms: Review the specific covenants and royalty obligations associated with the April 2026 Parkview credit facility, particularly the 75% net profit prepayment requirement and the lien on intellectual property.
• Stock-Based Compensation: Note the significant non-cash expense of $2.8 million in Q1 2026, which impacts net loss but not cash flow; verify future vesting schedules and dilution impact.
• Acquisition Integration: Monitor the progress and costs of the TBS-2025 program acquired from Kineta, which contributed to the increase in R&D spend.
• ATM Utilization: Track the pace of share sales under the ATM program, as this is a primary near-term source of equity capital.